Jeffrey Radding has joined Epitome Biosystems as vice president for research and development, the company announced this week.
Prior to joining Epitome, Radding headed the Platform Biology Group at Eli Lilly. The group evaluated and implemented cell signaling approaches for drug discovery across multiple therapeutic areas.
Radding obtained his PhD in chemistry from Indiana University.